Biogen has announced new data behind the Alzheimer's drug aducanumab suggests it was working on early stage patients. Jeff Borghoff was a participant for three years before the company halted the stage three clinical trial. He talks to Being Patient Alzheimer's about why he felt the drug was working.

Our mission is to give people impacted by dementia a better resource and connection to experts at the forefront of research. Our founder Deborah Kan funded Being Patient solely with her own savings to understand if people would value such a resource. Our audience has grown so rapidly, we have exciting plans for the future to enhance our coverage even further but we need your help. Please consider making a contribution to help fund Being Patient's editorial costs. We employ a team of journalists to give you the best possible information on dementia and brain health without bias.

To catch our Brain Talks live, join our Facebook page: [ Ссылка ]
For the latest news on dementia research and lifestyle tips, visit our site: [ Ссылка ]

свернуть